TRVI catalyst calendar

Trevi Therapeutics, Inc.

Upcoming catalysts
4
Cash runway
57.3 months
Cash & investments
$319M
Phase 3 programs
4

Trevi Therapeutics, Inc. is tracked here for clinical trial milestones, SEC filings and earnings dates. Focus area: Pharmaceutical Preparations.

The next scheduled catalyst is Next quarterly earnings (projected) on November 7, 2026, a projected date rather than a confirmed one. There are 4 upcoming events on record.

Cash runway is approximately 57.3 months based on the most recent reported cash position and quarterly operating burn as of 2026-06-30.

Across 14 concluded trials, 100% reached completion rather than being terminated or withdrawn.

Upcoming catalysts

DateEventTypePhase
November 7, 2026 est. Next quarterly earnings (projected) Earnings —
August 15, 2027 Idiopathic Pulmonary Fibrosis (IPF)-Related Chronic Cough Reduction With Nalbuphine (NAL) Extended-Release (ER) Tablets Trial Milestone Phase 3
September 15, 2027 The Effect of Nalbuphine Extended-Release (NAL ER) on Cough in Participants With Refractory Chronic Cough (RCC) Trial Milestone Phase 2
June 15, 2028 Idiopathic Pulmonary Fibrosis (IPF)-Related Chronic Cough Reduction With Nalbuphine Extended-Release (NAL ER) Tablets Trial Milestone Phase 3

Track TRVI alongside other companies. Add it to a watchlist and see every catalyst on one calendar.

Open TRVI in the tracker

Recent history

DateEventTypePhase
August 6, 2026 Quarterly results filed (8-K) Earnings —
June 30, 2026 NAL ER IPF Respiratory Function and Safety Study Trial Milestone Phase 1
May 11, 2026 A Food Effect Study to Evaluate the Relative Bioavailability of Nalbuphine Extended-Release Tablets (NAL ER) in Healthy Participants Trial Milestone Phase 1
May 5, 2026 Quarterly results filed (8-K) Earnings —
April 17, 2026 Quarterly results filed (8-K) Earnings —
March 17, 2026 Quarterly results filed (8-K) Earnings —
March 9, 2026 8-K filed: Other event Filing —
December 5, 2025 8-K filed: Leadership change Corporate —
November 13, 2025 Quarterly results filed (8-K) Earnings —
September 12, 2025 A Study of the Pharmacokinetic Interaction Between Pirfenidone, Nintedanib, and Nalbuphine Extended Release (NAL ER) in Healthy Participants Trial Milestone Phase 1
August 20, 2025 8-K filed: Leadership change Corporate —
August 7, 2025 Quarterly results filed (8-K) Earnings —
June 17, 2025 8-K filed: Leadership change Corporate —
June 4, 2025 8-K filed: Material agreement, Other event Corporate —
June 2, 2025 8-K filed: Other event Filing —
June 2, 2025 8-K filed: Other event Filing —
May 8, 2025 Quarterly results filed (8-K) Earnings —
April 24, 2025 Cough Reduction in IPF With Nalbuphine ER Trial Milestone Phase 2
January 6, 2025 Refractory Chronic Cough Improvement Via NAL ER (RIVER) Trial Milestone Phase 2
May 27, 2022 A Study of Nalbuphine (Extended Release) ER in Idiopathic Pulmonary Fibrosis (IPF) for Treatment of Cough Trial Milestone Phase 2
May 10, 2022 PRISM Study-Pruritus Relief Through Itch Scratch Modulation Trial Milestone Phase 2/Phase 3
February 5, 2020 Study of Nalbuphine ER in Participants With Hepatic Impairment Trial Milestone Phase 1
December 3, 2018 Oral Abuse Potential Study of Nalbuphine Trial Milestone Phase 1
September 3, 2017 Open Label Extension Study of Nalbuphine HCl ER in Patients With Prurigo Nodularis Trial Milestone Phase 2/Phase 3

About this data

Trial milestones come from the ClinicalTrials.gov v2 API, filings from SEC EDGAR, and financial figures from SEC XBRL company facts. Dates marked est. are projected rather than company-confirmed. This is an information tool, not investment advice — verify anything you act on against the linked primary source.

Last updated 2026-10-14.